“Latest Stem Cells News”

Cellular Dynamics International‘s disclosure Wednesday that its researchers have generated stem cells from ordinary human blood samples holds enormous promise in the emerging field of personalized medicine.

The promise in the long term is that, by giving a vial or two of blood, we could all have our own personal stem cells to deploy in the event of a spinal cord injury or the onset of Parkinson’s disease or many other now-incurable diseases.

Cellular Dynamics is the first company to say it can make stem cells from something as readily available, and so representative of human diversity, as blood.

“This stuff sounds like science fiction, but it’s science fact – and we’re doing it in a lab in Madison,” said Bob Palay, the Madison biotech company’s chairman and chief executive.

The discovery will allow the company in the near term to more easily provide a diverse mix of stem cells to researchers to help them understand the basis of disease and how to treat it, he said.

“It opens up all human tissue cells, in all human diversity, to pharmaceutical and academic researchers. It’s so huge, and so few people understand it,” Palay said.

The stem cells, which scientists refer to as induced pluripotent stem cells, or iPS cells, have all the characteristics of embryonic stem cells. They can turn into beating heart cells, liver cells or any other tissue cells in the body.

“From my knowledge of the market, there are companies out there that may be supplying a particular or specific cell type and offering it to industry, but CDI is doing it with a large suite of cells,” said Andy DeTienne, licensing manager for stem cells at the Wisconsin Alumni Research Foundation.

The foundation holds valuable patents on stem cell work done at the University of Wisconsin-Madison and has an ownership stake in Cellular Dynamics.

The company started out selling stem cell-derived heart cells to Roche and other pharmaceutical companies to help them test the toxicity of drugs.

The company has said it hopes to industrialize production of human cell types for research and create a bio-bank in which people could store stem cells engineered from their DNA for use in personalized therapies or in testing reactions to drugs.
Expanded deal with Roche

Cellular Dynamics said this month that it expanded its drug development testing agreement with Roche so that it will be supplying the drug industry giant with more iPS heart cells and other types of cells over the next two years. The companies also will collaborate to perform various tests on the cells.

Cellular Dynamics was formed in 2004 by stem cell pioneer James Thomson and three other UW researchers. The company has 65 employees and finished ramping up its stem cell production facility in June, Palay said. Cellular Dynamics has sales in the “multimillions” of dollars, he said.

Given its early lead in the industry and the additional products Cellular Dynamics is developing, DeTienne said he expects revenue to snowball.
Cellular Dynamics raised $18 million from mostly Wisconsin-based investors late last year.
Palay declined to comment about whether the company is trying to raise more financing.

from JSonline

Incoming search terms:

Kathrin Plath

UCLA researchers have found that embryonic stem cells and skin cells reprogrammed into embryonic-like cells have inherent molecular differences, demonstrating for the first time that the two cell types are clearly distinguishable from one another.

The data from the study suggest that embryonic stem cells and the reprogrammed cells, known as induced pluripotent stem (iPS) cells, have overlapping but still distinct gene expression signatures. The differing signatures were evident regardless of where the cell lines were generated, the methods by which they were derived or the species from which they were isolated, said William Lowry, a researcher with the Broad stem cell research center and a study author.

“We need to keep in mind that iPS cells are not perfectly similar to embryonic stem cells,” said Lowry, an assistant professor of molecular, cell and developmental biology. “We’re not sure what this means with regard to the biology of pluripotent stem cells. At this point our analyses comprise just an observation. It could be biologically irrelevant, or it could be manifested as an advantage or a disadvantage.”

The study appears in the July 2 issue of the journal Cell Stem Cell.

The iPS cells, like embryonic stem cells, have the potential to become all of the tissues in the body. However, iPS cells don’t require the destruction of an embryo. Some have touted iPS cells as replacements for embryonic stem cells. However, this study finds they are not identical as previously surmised. Researchers have maintained it is important to continue to study both cell types.

The study was a collaboration between the labs of Lowry and UCLA researcher Kathrin Plath. Lowry and Plath were among the first scientists worldwide and the first in California to reprogram human skin cells into iPS cells. The researchers performed microarray gene expression profiles on embryonic stem cells and iPS cells to measure the expression of thousands of genes at once, creating a global picture of cellular function.

Lowry and Plath noted that, when the molecular signatures were compared, it was clear that certain genes were expressed differently in embryonic stem cells than they were in iPS cells. They then compared their data to that stored on a National Institutes of Health data base, submitted by laboratories worldwide. They analyzed that data to see if the genetic profiling conducted in other labs validated their findings, and again they found overlapping but distinct differences in gene expression, Lowry said.

Incoming search terms:

Fondazione IRCCS Istituto Nazionale Tumori di Milano

Methods to provide safer stem cell transplants to individuals who are not completely compatible with the donor are being developed. Encouraging results have come from a post-transplant cellular therapy, which strengthens the immune system against viral infections and tumors, developed for the first time at the National Tumor Institute (INT) in Milan. The INT conducted the first phase I-II study in the world, published in ‘Blood’, whose main objective was to assess the use of a low dose radiochemotherapy, followed by low dose post-transplant infusions CD8-depleted donor lymphocytes after a 50% compatible hematopoietic stem cell transplant.

The objective of the study was to reduce transplant toxicity and improve immune system function after the transplant to reduce mortality due to infections and relapses. Stem cell transplants from fully compatible donors (HLA-identical) are an option for many individuals with blood-borne cancers. However, only 50-60% of these patients are able to find a fully compatible donor in their families or on the international donor registry. For leukemia and lymphoma patients with a high risk for early relapse who are not able to find an identical donor, the only concrete alternative is a transplant from a 50% compatible family donor (haploidentical donor) or umbilical cord stem cell transplants for child or low weight patients.

In the past, the use of partially compatible donors was prevented by severe side effects. New strategies to improve results are increasingly necessary. Twenty-eight adult patients affected by advanced hematological neoplasias who had no other alternative treatment in order to survive took part in the study. Twenty-four of the patients were suffering from lymphoma and four from acute leukemia.

Transplant-related mortality after two years was reduced from 40-50% to 25%. The two-year global survival rate was 44% with a better result for patients with chemosensitive diseases (2-year survival rate of 75%).
On the whole, 54 CD8 depleted donor lymphocyte infusions were performed on 23 patients, using three different doses of cells with the objective of defining which dose favored an efficient reconstitution of immunity against infective agents and residual tumor cells, reducing the probability of inducing aggressive immune responses against the recipient. The infusions were well tolerated by the patients and did not reduce the transplant from taking root and did not induce acute toxicity.

At the base of the neck is located a reserve of stem cells that could revolutionize the fight against obesity and diabetes. These fat-burning stem cells are the mother cells of brown adipose tissue, and a study coordinated by Italian researcher Saverio Cinti of the Marches region Polytechnic Institute discovered them. The results of the study were presented at the European Obesity Congress in Amsterdam and published in Faseb Journal, the magazine of the Federation of American experimental biology societies.

“It is possible to cultivate these stem cells to grow brown adipose tissue that can be transplanted into individuals to treat serious cases of obesity or diabetes,” explained Cinti. We will be able to control excess weight gain with cold temperatures, in addition to diet and physical exercise: “cold temperatures stimulate brown adipose, and it is sufficient to maintain a temperature of 18 degrees Celsius in order to increase its function”.

- BROWN AND WHITE TISSUE: are the two components of adipose tissue, which is actually considered by scientists to be an organ. White fat accumulates fat cells and in the past has played a decisive role in helping humans tolerate long periods without food. Now it is mainly blamed for the dreaded ‘belly’. On the other hand, brown fat cells burn fat and consume glucose.

Brown fat is abundant in infants and until a short while ago, it was believed that this highly important reserve disappeared with age. Recent studies, some of which were conducted by Cinti’s group, have observed brown adipose reserves in adults. Now it has been discovered that there is a reserve of brown fat cells that exist in adults.

- FAT-BURNING STEM CELLS PRESENT IN ONE OUT OF THREE ADULTS: the discovery is based on tissue biopsies on 35 individuals who underwent thyroid operations. “We found brown adipose tissue stem cells in one-third of the patients. This result,” observed Cinti, “confirms statistical data showing that this tissue is highly present in young and thin individuals. Individuals who are not thin are probably born with less brown adipose tissue.”

- FAT-BURNING TISSUE FACTORIES: knowing where to find brown fat stem cells means being able to cultivate them in order to transplant them into patients affected by obesity or diabetes.

- ACTIVATING BROWN FAT STEM CELLS: is another strategy that is now becoming possible. Stimulating stem cells involves stimulating the growth of brown fat in order to activate a natural mechanism that burns fat.

- COLD TEMPERATURES BURN MORE FAT TISSUE: together with diet and physical exercise, cold temperatures are becoming an important ally to combat excess weight and obesity. Keeping a low temperature at home during the winter (around 18 degrees Celsius) or walking in the cold helps burn fat and glucose. Calculations show that 50 to 100 grams of brown fat tissue result in a loss of 4-5kg per year.

Incoming search terms:

Research in Italy, in the coming years, will suffer much more compared to research in other countries, because, explained a study on the future of biomedical research in Italy described yesterday in Siena by Stefano Palumbo, “the national debate on bioethical issues will continue to be affected by pre-established ideological positions, and often, will be aimed at imposing limits on scientific research”.

Due to the overwhelming “majority of Catholic members in the National Bioethics Committee, Italy will be,” according to the study, “the most conservative country in the world regarding stem cells,” which will result in great delays in finding treatments for serious diseases like “diabetes, Parkinson’s, cancer, Huntington’s, and Alzheimer’s”.

Between 2009 and 2015, Italian research will be affected by the economic crisis, and, according to the study, which was financed by the MPS Foundation and Siena Biotech, “will also be affected by the crisis in the pharmaceutical sector, resulting from the expiration of patents and the inability to replace products whose patents have expired with new products”. According to the experts, Italian research groups will be increasingly dependent on international financing.

Incoming search terms:

The South Korean bioethics committee has lifted a ban on human stem cell research. The decision will now allow for work on human embryonic stem cells to resume after being interrupted three years ago following the scandal involving Hwang Woo-suk, the false “pioneer of human cloning”. The veterinarian, a national hero at the time, fell from grace after the international scientific community and the University of Seoul uncovered that results from his research on embryonic stem cells were falsified in the laboratory to give the impression that his group was successful in cloning healthy cells from cells affected by incurable diseases.

The lifting of the research ban, explained the bioethics committee, involves a hospital in Seoul (Cha General Hospital), which will resume research under four conditions: written approval from women donating eggs (only those from aborted fetuses will be used); the use of laboratory animals to reduce the use of these eggs to a minimum; instituting a surveillance committee to avoid abuses; the names of the studies must not refer to words or meanings that could “feed false hopes”, including mentioning “cure for Parkinson’s”. The decision to lift the ban must receive authorization from the Health Ministry, and in all likelihood, it will not be rejected.

South Korea seems to be following the policy decisions regarding bioethics of the American administration. Among the steps taken by US President Barack Obama, is also the decision to resume financing for human stem cell research with an initial allocation of one billion dollars. “The decision will restart research,” said Chung Hyung-Min, who pointed out that such studies “have been performed by English scientists and other countries” but until now “there have not scored any successes”.

Embryonic stem cell research has sparked a heated worldwide debate involving ethics, science, and the right to life. The position of the Catholic Church has always been that it considers embryos as human lives. In May of 2008, bishops confirmed strongly condemned the revisions of the law on bioethics approved by Parliament, which allow for those who accept to participate in cloning experiments to be eligible for “reimbursements of their expenses”.

Incoming search terms: